Scripps experts identify new anti-diabetes compound

09/6/2011 | Diabetes.co.uk (U.K.) · NewKerala.com (India)

Researchers at the Scripps Research Institute in Florida have identified a new class of anti-diabetes compound that may aid in the development of drug therapies with fewer adverse side effects for those with pre-diabetes and type 2 diabetes. Researchers said the compound, SR1664, will serve as molecular scaffolding to create similar compounds to treat the disease, according to the study in the journal Nature.

View Full Article in:

Diabetes.co.uk (U.K.) · NewKerala.com (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX